DEEJ(000423)2025-01-17 14:15Financial Performance - The company expects a net profit attributable to shareholders of between 150,000 and 160,000 million yuan, representing an increase of 30% to 39% compared to the previous year's profit of 115,087.86 million yuan[3]. - The expected net profit after deducting non-recurring losses is projected to be between 140,000 and 150,000 million yuan, up from 108,262.85 million yuan last year, indicating a growth of 29% to 39%[3]. - The basic earnings per share are anticipated to be between 2.33 yuan and 2.49 yuan, compared to 1.79 yuan per share in the previous year[3]. - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report[7]. Strategic Focus - The company is focusing on a "growth and quality" development theme and is implementing the "1238" development strategy to enhance operational performance[5]. - The company aims to strengthen its core business in the traditional Chinese medicine sector while expanding potential product lines and enhancing digital capabilities[6]. - The company is committed to a dual-driven growth model of "medicinal products + health consumer goods" to solidify its market position[6]. - The company plans to innovate and expand its product offerings, including the "Royal Weichang 1619" men's health product line and the "Zhuangben" meat supplement category[6]. Brand and Market Positioning - The company emphasizes the importance of brand recognition and influence through integrated marketing and innovative channel communication[6]. - The company is dedicated to becoming a trusted leader in health supplements for the public, focusing on high-quality and sustainable growth[6].